+29.7%
DAL vs MRNA
+451.7%
-422.0%
-22.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.3% | -3.4% | +3.1% | -0.3% |
| 7D | +0.8% | -10.1% | +10.9% | +0.8% |
| 30D | -11.7% | +126.7% | -138.5% | -12.0% |
| 3M | -2.7% | +184.1% | -186.9% | -6.0% |
| 6M | +30.7% | +143.3% | -112.6% | +27.4% |
| YTD | +14.4% | +359.9% | -345.5% | +6.6% |
| All | +29.7% | +451.7% | -422.0% | +20.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling